Adamantiades Behets Disease TABLE 3 Treatment of Behets Disease

Mild mucocutaneous disease Topical anesthetics Topical or intralesional corticosteroids Topical tacrolimus Topical tetracycline solutions Oral tetracycline or macrolide agents Topical amlexanox (paste) Sucralfate Oral colchicine

Oral dapsone (25-200 mg daily) Antimalarials

Rebamipide (mucoprotective agent) Severe mucocutaneous disease Thalidomide

Oral corticosteroids (0.5-1.0 mg/kg/day) Methotrexate Azathioprine Interferon-a Anti-TNF-a agents Systemic disease

Systemic corticosteroids Intravenous immunoglobulin Sulfasalazine Methotrexate Azathioprine Cyclophosphamide Chlorambucil Cyclosporine Anti-TNF-a agents Ocular disease

Corticosteroids (including intraocular injection)

Cyclophosphamide

Chlorambucil

Azathioprine

Cyclosporine

Consideration of early use of anti-TNF-a agents (infliximab) Pulmonary or thrombotic disease

Pulmonary or aortic aneurysms—systemic corticosteroids, cytotoxic agents

Superficial thrombophlebitis—local therapies, aspirin, nonsteroidal anti-inflammatory agents

Deep venous thrombosis—heparin, warfarin

Abbreviation: TNF, tumor necrosis factor.

0 0

Post a comment